Pavlusova M, et al. - Researchers used a large cohort to evaluate the beneficial impacts of allopurinol treatment for hyperuricemia in patients with heart failure (HF). They identified 3,160 hospitalized patients from the prospective acute heart failure registry who had a known level of uric acid (UA) and were discharged in stable condition. They defined hyperuricemia as UA ≥500μmol/l and/or allopurinol treatment at admission. In HF patients, an unfavorable cardiovascular risk profile was observed in relation to hyperuricemia. No improvement in the prognosis was evident when low doses of allopurinol were used to treat HF patients. A comparable five-year survival rate was seen in patients without hyperuricemia vs those with untreated hyperuricemia; patients with treated hyperuricemia had a worse prognosis.